Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
Status: | Completed |
---|---|
Conditions: | Prostate Cancer, Cancer, Neurology |
Therapuetic Areas: | Neurology, Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/4/2013 |
Start Date: | August 2009 |
End Date: | October 2013 |
Contact: | Erick DeVinney |
Email: | edevinney@axogeninc.com |
Phone: | 386-462-6829 |
A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy
The purpose of this study is to determine if it is technically feasable to repair nerves
that are injured as part of a planned surgical removal of the prostate and the surrounding
tissue in subjects with prostate cancer. The study will also examine the long term outcomes
on erectile function, continence and overall quality of life in the enrolled subjects.
Inclusion Criteria:
- ≥ 18 years of age, but ≤70 years of age;
- IIEF EF Domain*1 score ≥ 22;
- be able to effectively communicate with study personnel;
- be considered by the physician to be available for subsequent visits;
- be willing to comply with all aspects of the treatment and evaluation schedule over a
24 month duration;
- sign and date an IRB-approved written informed consent prior to initiation of any
study procedures, including screening procedures; and
- require radical prostatectomy.
Exclusion Criteria:
- prior surgery in the last 6 months which could affect sexual function;
- history of Peyronie's disease;
- significant neurological disorder (i.e. multiple sclerosis, peripheral neuropathy);
- treatment for major psychiatric disorders;
- history of penile implant or prosthesis;
- history of diabetic neuropathy;
- life expectancy of less than two years;
- concurrently involved in another investigational study;
- uncontrolled hypertension with systolic BP >200mmHg or diastolic BP >115mmHg is
present at screening;
- currently receiving or planned treatment with chemotherapy or radiation therapy;
- diagnosis of bony metastasis;
- known allergy or severe intolerance to PDE-5 inhibitors; or
- cardiac pacing equipment or other electro-mechanical devices which preclude the use
of CaverMap™ neurostimulator.
We found this trial at
1
site
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
Click here to add this to my saved trials